TransCode Therapeutics’ (RNAZ) “Buy” Rating Reiterated at HC Wainwright

TransCode Therapeutics (NASDAQ:RNAZ)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report released on Tuesday, Benzinga reports.

TransCode Therapeutics Trading Down 3.4 %

TransCode Therapeutics stock traded down $0.02 during mid-day trading on Tuesday, hitting $0.49. The company’s stock had a trading volume of 112,982 shares, compared to its average volume of 612,573. TransCode Therapeutics has a 1 year low of $0.47 and a 1 year high of $356.00. The firm has a market capitalization of $2.82 million, a PE ratio of 0.00 and a beta of -0.35. The stock’s fifty day moving average is $0.67 and its two-hundred day moving average is $6.24.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of RNAZ. Renaissance Technologies LLC purchased a new stake in shares of TransCode Therapeutics in the 2nd quarter valued at approximately $25,000. Citadel Advisors LLC purchased a new stake in TransCode Therapeutics in the fourth quarter valued at approximately $46,000. UBS Group AG purchased a new position in shares of TransCode Therapeutics during the third quarter worth $74,000. Sabby Management LLC lifted its stake in TransCode Therapeutics by 32.8% during the 3rd quarter. Sabby Management LLC now owns 250,309 shares of the company’s stock worth $126,000 after acquiring an additional 61,872 shares in the last quarter. Finally, Worth Venture Partners LLC boosted its holdings in TransCode Therapeutics by 9.7% during the 1st quarter. Worth Venture Partners LLC now owns 324,157 shares of the company’s stock valued at $934,000 after acquiring an additional 28,617 shares during the period.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.